Piper Sandler Reiterates Overweight Rating on Sutro Biopharma (STRO)

Go back to Piper Sandler Reiterates Overweight Rating on Sutro Biopharma (STRO)

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

September 14, 2024 3:00 AM UTC

- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose (RP2D) -

- Luvelta in combination with bevacizumab demonstrated encouraging preliminary antitumor activity (35% response rate) across all explored dose ranges -

- Expansion at RP2D is ongoing with an additional 23 patients enrolled to date; expansion data are expected in the first half of 2025 -

- No... More

World’s First AutoStore™ Installation Handling Frozen Goods Installed by StrongPoint

September 13, 2024 3:00 AM UTC

OSLO, Norway--(BUSINESS WIRE)-- StrongPoint, a retail technology firm focused on making stores and supply chains smarter, have successfully installed the world's first AutoStore Multi-Temperature Solution with a frozen zone. The inaugural site has been installed for Haugaland Storhusholdning, part the Norwegian food distribution group DLVRY, in a facility based in Sveio, Norway.

This press release features multimedia. View the full... More